908 Devices Inc. (MASS) Stock Competitors & Peer Comparison
See (MASS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MASS | $7.35 | -0.81% | 301.5M | -12.25 | -$0.60 | N/A |
| ALC | $70.26 | -0.51% | 34.3B | 22.09 | $3.18 | +0.51% |
| PHG | $26.95 | -1.25% | 26.2B | 15.40 | $1.75 | +3.69% |
| STE | $217.84 | -1.49% | 21.2B | 21.41 | $10.17 | +1.16% |
| BRKRP | $434.02 | -1.16% | 8.9B | 855.41 | $0.51 | +0.35% |
| DRTSW | $3.75 | +26.69% | 1.2B | -5.81 | -$0.65 | N/A |
| SI | $21.59 | -4.17% | 447.7M | -11.28 | -$1.91 | N/A |
| MOBI | $12.15 | +1.08% | 404M | -0.65 | -$18.78 | N/A |
| CV | $6.71 | +5.01% | 335.3M | -2.68 | -$2.50 | N/A |
| APYX | $4.28 | -1.38% | 179.4M | -19.45 | -$0.22 | N/A |
Stock Comparison
MASS vs ALC Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, ALC has a market cap of 34.3B. Regarding current trading prices, MASS is priced at $7.35, while ALC trades at $70.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas ALC's P/E ratio is 22.09. In terms of profitability, MASS's ROE is -0.26%, compared to ALC's ROE of +0.04%. Regarding short-term risk, MASS is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ALC's competition here
MASS vs PHG Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, PHG has a market cap of 26.2B. Regarding current trading prices, MASS is priced at $7.35, while PHG trades at $26.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas PHG's P/E ratio is 15.40. In terms of profitability, MASS's ROE is -0.26%, compared to PHG's ROE of +0.09%. Regarding short-term risk, MASS is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check PHG's competition here
MASS vs STE Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, STE has a market cap of 21.2B. Regarding current trading prices, MASS is priced at $7.35, while STE trades at $217.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas STE's P/E ratio is 21.41. In terms of profitability, MASS's ROE is -0.26%, compared to STE's ROE of +0.11%. Regarding short-term risk, MASS is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check STE's competition here
MASS vs BRKRP Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, BRKRP has a market cap of 8.9B. Regarding current trading prices, MASS is priced at $7.35, while BRKRP trades at $434.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas BRKRP's P/E ratio is 855.41. In terms of profitability, MASS's ROE is -0.26%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, MASS is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BRKRP's competition here
MASS vs DRTSW Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, DRTSW has a market cap of 1.2B. Regarding current trading prices, MASS is priced at $7.35, while DRTSW trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas DRTSW's P/E ratio is -5.81. In terms of profitability, MASS's ROE is -0.26%, compared to DRTSW's ROE of -0.73%. Regarding short-term risk, MASS is less volatile compared to DRTSW. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check DRTSW's competition here
MASS vs SI Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, SI has a market cap of 447.7M. Regarding current trading prices, MASS is priced at $7.35, while SI trades at $21.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas SI's P/E ratio is -11.28. In terms of profitability, MASS's ROE is -0.26%, compared to SI's ROE of -0.35%. Regarding short-term risk, MASS is less volatile compared to SI. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check SI's competition here
MASS vs MOBI Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, MOBI has a market cap of 404M. Regarding current trading prices, MASS is priced at $7.35, while MOBI trades at $12.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas MOBI's P/E ratio is -0.65. In terms of profitability, MASS's ROE is -0.26%, compared to MOBI's ROE of +0.31%. Regarding short-term risk, MASS is more volatile compared to MOBI. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check MOBI's competition here
MASS vs CV Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, CV has a market cap of 335.3M. Regarding current trading prices, MASS is priced at $7.35, while CV trades at $6.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas CV's P/E ratio is -2.68. In terms of profitability, MASS's ROE is -0.26%, compared to CV's ROE of +1.27%. Regarding short-term risk, MASS is less volatile compared to CV. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check CV's competition here
MASS vs APYX Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, APYX has a market cap of 179.4M. Regarding current trading prices, MASS is priced at $7.35, while APYX trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas APYX's P/E ratio is -19.45. In terms of profitability, MASS's ROE is -0.26%, compared to APYX's ROE of -0.91%. Regarding short-term risk, MASS is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check APYX's competition here
MASS vs EDAP Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, MASS is priced at $7.35, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas EDAP's P/E ratio is -5.80. In terms of profitability, MASS's ROE is -0.26%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, MASS is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check EDAP's competition here
MASS vs HYPR Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, HYPR has a market cap of 82.7M. Regarding current trading prices, MASS is priced at $7.35, while HYPR trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas HYPR's P/E ratio is -2.46. In terms of profitability, MASS's ROE is -0.26%, compared to HYPR's ROE of -1.01%. Regarding short-term risk, MASS is less volatile compared to HYPR. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check HYPR's competition here
MASS vs NYXH Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, NYXH has a market cap of 62.2M. Regarding current trading prices, MASS is priced at $7.35, while NYXH trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas NYXH's P/E ratio is -0.63. In terms of profitability, MASS's ROE is -0.26%, compared to NYXH's ROE of -1.64%. Regarding short-term risk, MASS is more volatile compared to NYXH. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check NYXH's competition here
MASS vs MDAI Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, MDAI has a market cap of 53.1M. Regarding current trading prices, MASS is priced at $7.35, while MDAI trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas MDAI's P/E ratio is -3.71. In terms of profitability, MASS's ROE is -0.26%, compared to MDAI's ROE of +1.79%. Regarding short-term risk, MASS is more volatile compared to MDAI. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check MDAI's competition here
MASS vs VNRX Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, VNRX has a market cap of 9.2M. Regarding current trading prices, MASS is priced at $7.35, while VNRX trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas VNRX's P/E ratio is -0.52. In terms of profitability, MASS's ROE is -0.26%, compared to VNRX's ROE of +0.74%. Regarding short-term risk, MASS is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check VNRX's competition here
MASS vs WOK Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, WOK has a market cap of 4.8M. Regarding current trading prices, MASS is priced at $7.35, while WOK trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas WOK's P/E ratio is N/A. In terms of profitability, MASS's ROE is -0.26%, compared to WOK's ROE of -0.07%. Regarding short-term risk, MASS is more volatile compared to WOK. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check WOK's competition here
MASS vs BIAFW Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, BIAFW has a market cap of 3.6M. Regarding current trading prices, MASS is priced at $7.35, while BIAFW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas BIAFW's P/E ratio is 0.34. In terms of profitability, MASS's ROE is -0.26%, compared to BIAFW's ROE of -3.59%. Regarding short-term risk, MASS is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BIAFW's competition here
MASS vs QTEXW Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, QTEXW has a market cap of 3.5M. Regarding current trading prices, MASS is priced at $7.35, while QTEXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas QTEXW's P/E ratio is -0.05. In terms of profitability, MASS's ROE is -0.26%, compared to QTEXW's ROE of N/A. Regarding short-term risk, MASS is less volatile compared to QTEXW. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check QTEXW's competition here
MASS vs ITOC Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, ITOC has a market cap of 2.8M. Regarding current trading prices, MASS is priced at $7.35, while ITOC trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas ITOC's P/E ratio is -0.97. In terms of profitability, MASS's ROE is -0.26%, compared to ITOC's ROE of -0.94%. Regarding short-term risk, MASS is less volatile compared to ITOC. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check ITOC's competition here
MASS vs FEED Comparison July 2026
MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASS stands at 301.5M. In comparison, FEED has a market cap of 450.5K. Regarding current trading prices, MASS is priced at $7.35, while FEED trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASS currently has a P/E ratio of -12.25, whereas FEED's P/E ratio is -0.01. In terms of profitability, MASS's ROE is -0.26%, compared to FEED's ROE of -0.44%. Regarding short-term risk, MASS is less volatile compared to FEED. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check FEED's competition here